Abstract
New oral anticoagulants(NOAC) including dabigatran, rivaroxaban, apixaban and edoxaban have been widely used clinically. These drugs are the direct coagulation factor inhibitor. They have the stable pharmacokinetics so that patients don't require routine coagulation monitoring. They can be administrated in fixed doses and have few drug interactions. NOAC have been recommended in 2014 guideline for the management of patients with atrial fibrillation by American Heart Association, American College of Cardiology and Heart Rhythm Society. NOAC can be a replacement in patients who have contraindications for warfarin. The dose-adjustment of NOAC is based on the particular pharmacokinetic characteristics and kidney function of the elderly. Pharmaceutical care plan is helpful to increase the safety and efficacy of the medication in the elderly. Key words: Anticoagulants; Atrial fibrillation; Aged
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
